KRAS and familial pancreatic carcinoma: For example, ILK could regulate the sensitivity of pancreatic cancer cells to gemcitabine [16], and the pharmacological inhibition of ILK in oncogene homolog (KRAS) mutant lung cancer cells could inhibit cell growth, migration, and epithelial mesenchymal transition, and increase sensitivity to CDDP chemotherapy [30].